Webinar Recorded on May 4, 2016
Click here to download PDF of presentation
Since its initial release in 2000, the AMCP Format for Formulary Submissions has provided a framework to advise drug manufacturers regarding important payer evidence requirements related to evaluating new technologies for formulary consideration. Discussion leaders will provide an overview of key updates to the Format, Version 4.0, including new guidance related to emerging special topic considerations such as biosimilars, specialty drugs, and companion diagnostic tests. Modifications to improve the usability of the Format, with clarifying guidance related to logistical considerations such as evidence placement, dossier updates, and recommended implementation timelines, will be discussed.
- Jeff Lee, PharmD, FCCP, Associate Professor of Pharmacy Practice, Lipscomb University College of Pharmacy (Format Executive Committee Chair)
- Pete Penna, PharmD, President, Formulary Resources, LLC (Clinical Evidence Work Group)
- Kim Saverno, PhD, RPh, Research Lead, Comprehensive Health Insights, Humana (Economic Evidence Work Group)
- Iris Tam, PharmD, Vice President, Patient Access and Quality, Medical Affairs, Otonomy, Inc. (General Information Work Group)